These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 23024035)

  • 21. Inference on the rate ratio of recurrent events for the matched pairs design.
    Sumi M; Tango T
    Stat Med; 2010 Dec; 29(30):3186-93. PubMed ID: 21170912
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sample size determination and re-estimation for matched pair designs with multiple binary endpoints.
    Xu J; Yu M
    Biom J; 2013 May; 55(3):430-43. PubMed ID: 23553605
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A behavioural Bayes approach to the determination of sample size for clinical trials considering efficacy and safety: imbalanced sample size in treatment groups.
    Kikuchi T; Gittins J
    Stat Methods Med Res; 2011 Aug; 20(4):389-400. PubMed ID: 20223784
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A tale of two SCIDs.
    Shaw KL; Kohn DB
    Sci Transl Med; 2011 Aug; 3(97):97ps36. PubMed ID: 21865536
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An adaptive design to bridge the gap between Phase 2b/3 microbicide effectiveness trials and evidence required for licensure.
    Taylor DJ; Grobler A; Abdool Karim SS
    Clin Trials; 2012 Aug; 9(4):377-84. PubMed ID: 22610168
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An examination of the efficiency of the sequential parallel design in psychiatric clinical trials.
    Tamura RN; Huang X
    Clin Trials; 2007; 4(4):309-17. PubMed ID: 17848492
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sample size determination in superiority clinical trials with multiple co-primary correlated endpoints.
    Sozu T; Sugimoto T; Hamasaki T
    J Biopharm Stat; 2011 Jul; 21(4):650-68. PubMed ID: 21516562
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Conditional analysis of mixed Poisson processes with baseline counts: implications for trial design and analysis.
    Cook RJ; Wei W
    Biostatistics; 2003 Jul; 4(3):479-94. PubMed ID: 12925513
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Two-stage design of clinical trials involving recurrent events.
    Cook RJ; Bergeron PJ; Boher JM; Liu Y
    Stat Med; 2009 Sep; 28(21):2617-38. PubMed ID: 19579215
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neonatal screening for severe combined immunodeficiency caused by an adenosine deaminase defect: a reliable and inexpensive method using tandem mass spectrometry.
    Azzari C; la Marca G; Resti M
    J Allergy Clin Immunol; 2011 Jun; 127(6):1394-9. PubMed ID: 21624616
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sample size estimation for non-inferiority trials of time-to-event data.
    Crisp A; Curtis P
    Pharm Stat; 2008; 7(4):236-44. PubMed ID: 17583558
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The design and analysis of randomized trials with recurrent events.
    Cook RJ
    Stat Med; 1995 Oct; 14(19):2081-98. PubMed ID: 8552888
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The importance of varying the event generation process in simulation studies of statistical methods for recurrent events.
    Metcalfe C; Thompson SG
    Stat Med; 2006 Jan; 25(1):165-79. PubMed ID: 16217859
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase II cancer clinical trials with a one-sample log-rank test and its corrections based on the Edgeworth expansion.
    Sun X; Peng P; Tu D
    Contemp Clin Trials; 2011 Jan; 32(1):108-13. PubMed ID: 20888929
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Formulae and tables for the determination of sample sizes and power in clinical trials for testing differences in proportions for the two-sample design: a review.
    Sahai H; Khurshid A
    Stat Med; 1996 Jan; 15(1):1-21. PubMed ID: 8614740
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Two-stage k-sample designs for the ordered alternative problem.
    Shan G; Hutson AD; Wilding GE
    Pharm Stat; 2012; 11(4):287-94. PubMed ID: 22408050
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sample size determination based on rank tests in clinical trials.
    Wang H; Chen B; Chow SC
    J Biopharm Stat; 2003 Nov; 13(4):735-51. PubMed ID: 14584719
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Design of adaptive two-stage double-arm clinical trials for dichotomous variables.
    Jiang Z; Xue F; Li C; Wang L; Cai H; Zhang C; Xia J
    Contemp Clin Trials; 2010 May; 31(3):242-50. PubMed ID: 20172053
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A practical comparison of blinded methods for sample size reviews in survival data clinical trials.
    Todd S; Valdés-Márquez E; West J
    Pharm Stat; 2012; 11(2):141-8. PubMed ID: 22337635
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sample size calculation for the Power Model for dose proportionality studies.
    Sethuraman VS; Leonov S; Squassante L; Mitchell TR; Hale MD
    Pharm Stat; 2007; 6(1):35-41. PubMed ID: 17323313
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.